Publications by authors named "Jean Jacques Body"
Purpose: Sandoz biosimilar denosumab (GP2411 [SDZ-deno]; Jubbonti/Wyost) is approved by the US FDA, EMA and Health Canada for all indications of reference denosumab (REF-deno; Prolia/Xgeva), a fully human IgG2κ monoclonal antibody that binds with high affinity and specificity to receptor activator of nuclear factor kappa-B ligand (RANKL). Denosumab blocks RANKL, preventing bone resorption and loss of bone density/architecture in conditions characterized by excessive bone loss such as osteoporosis in postmenopausal women and metastatic bone disease, among others.
Methods: This narrative review summarizes the totality of evidence (ToE) for SDZ-deno that supported its approval as Jubbonti/Wyost in the EU and US.
Article Synopsis
- Low vitamin D levels are linked to various health problems, making people and doctors interested in checking vitamin D levels more often.
- Most health guidelines don't suggest checking vitamin D levels for everyone, but rather for specific groups who might need it the most.
- There are many different opinions on how to test for vitamin D, and it's important to align these guidelines to make testing easier and more effective for everyone.
Denosumab is a monoclonal antibody used to reduce risk of fractures in osteoporosis. ROSALIA was a multicenter, double-blind, randomized, integrated phase I/phase III study comparing the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and safety of proposed biosimilar denosumab GP2411 with reference denosumab (REF-DMAb) (Prolia®; Amgen). Postmenopausal women with osteoporosis were randomized 1:1 to 2 60-mg doses of GP2411 or REF-DMAb, one at study start and one at week 26.
View Article and Find Full Text PDFUnlabelled: Only previous glucocorticoid use and rheumatoid arthritis were predictors of an early fracture (< 2 years after inclusion). A shorter 'time to first fracture' was not an independent clinical risk factor for imminent fractures.
Purpose: Risk factors for fragility fractures independent of BMD were assessed in several prediction models.
Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
BMJ
May 2023
Article Synopsis
- This study looks at how well different osteoporosis treatments work to prevent fractures in postmenopausal women.
- They analyzed many clinical trials from different sources, focusing on various treatments like bisphosphonates and romosozumab.
- The results showed that some treatments were better at protecting against fractures than others, with bisphosphonates and certain hormone treatments being more effective.
Article Synopsis
- The FRISBEE fracture risk prediction models were tested on a group of 9716 Canadian women, revealing that while they showed strong discriminatory ability, they tended to overestimate fracture risk.
- The study aimed to validate these prediction models for fractures, major osteoporotic fractures (MOFs), and central fractures using data from women's BMD assessments in Manitoba.
- Results indicated effective risk stratification (AUROC values of 0.69 to 0.72), with a notable gradient of risk increase for women, indicating that those with higher risk scores had significantly higher odds of experiencing fractures.
Article Synopsis
- Tumor-induced osteomalacia (TIO) is a rare condition linked to mesenchymal tumors that produce fibroblast growth factor 23 (FGF23), leading to symptoms like bone pain, muscle weakness, and fractures, along with specific biochemical abnormalities.
- Limited awareness of TIO in the medical field often results in delayed diagnosis and negative outcomes, prompting the need for clearer guidance on its recognition and management.
- A global guidance document has been developed, outlining diagnostic recommendations, necessary laboratory tests, and treatment options such as tumor resection or phosphate supplementation, aiming to standardize patient care and improve outcomes for those affected by TIO.
Unlabelled: We registered 1336 incident-validated fractures in a prospective cohort of 3560 postmenopausal (60-85 years) Belgian women (mean follow-up of 9.1 years). The increase of fracture incidence with age varied widely depending on the fracture site and was significantly steeper for central than for peripheral fractures (e.
View Article and Find Full Text PDFTumor-induced osteomalacia (TIO) is a rare and largely underdiagnosed paraneoplastic condition. Previous reviews often reported incomplete data on clinical aspects, diagnosis or prognosis. The aim of this study was to present a systematic clinical review of all published cases of TIO.
View Article and Find Full Text PDFGlucocorticoids are effective immunomodulatory drugs used for many inflammatory disorders as well as in transplant recipients. However, both iatrogenic and endogenous glucocorticoid excess are also associated with several side effects including an increased risk of osteoporosis and fractures. Glucocorticoid-induced osteoporosis (GIOP) is a common secondary cause of osteoporosis in adults.
View Article and Find Full Text PDFResponse to Letter to the Editor From Taguchi: "Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS".
J Clin Endocrinol Metab
May 2022
Context: Individualized fracture risk may help to select patients requiring a pharmacological treatment for osteoporosis. FRAX and the Garvan fracture risk calculators are the most used tools, although their external validation has shown significant differences in their risk prediction ability.
Objective And Methods: Using data from the Fracture Risk Brussels Epidemiological Enquiry study, a cohort of 3560 postmenopausal women aged 60 to 85 years, we aimed to construct original 5-year fracture risk prediction models using validated clinical risk factors (CRFs).
Context: Antiresorptive therapy significantly reduces fracture risk in patients with benign bone disease and skeletal-related events (SREs) in patients with bone metastases (BM). Osteonecrosis of the jaw (ONJ) is a rare but severe condition manifested as necrotic bone lesion or lesions of the jaws. ONJ has been linked to the use of potent antiresorptive agents, termed medication-related ONJ (MRONJ).
View Article and Find Full Text PDFContext: Numerous studies have demonstrated detrimental skeletal consequences following bariatric surgery.
Methods: A working group of the European Calcified Tissue Society (ECTS) performed an updated review of existing literature on changes of bone turnover markers (BTMs), bone mineral density (BMD), and fracture risk following bariatric surgery and provided advice on management based on expert opinion.
Literature Review: Based on observational studies, bariatric surgery is associated with a 21-44% higher risk of all fractures.
Probabilistic models including clinical risk factors with or without bone mineral density (BMD) have been developed to estimate the 5- or 10-year absolute fracture risk. We investigated the performance of the FRAX and Garvan tools in a well-characterized population-based cohort of 3560 postmenopausal, volunteer women, aged 60 to 85 years at baseline, included in the Fracture Risk Brussels Epidemiological Enquiry (FRISBEE) cohort, during 5 years of follow-up. Baseline data were used to calculate the estimated 10-year risk of hip and major osteoporotic fractures (MOFs) for each participant using FRAX (Belgium).
View Article and Find Full Text PDFArticle Synopsis
- Patients who've had a fracture are at increased risk for another one in the next two years, particularly older women aged 60 to 85, with the study analyzing a cohort of 3,560 postmenopausal women.
- Three models were created to predict imminent fractures based on factors like bone mineral density, fall history, and comorbidities; these models showed good predictive accuracy compared to established tools like FRAX.
- The models use five key predictors (BMD, age, comorbidities, falls, and history of central fractures) to assess fracture risk and are presented as user-friendly nomograms for clinical use.
Purpose: To provide a summarized state of the art of the relative efficacy and rapidity of action of pharmacological treatments to prevent imminent osteoporotic fractures.
Methods: We reviewed metanalyses (MA) and network metaanalyses (NMA) published during the last 10 years concerning the pharmacological treatment of osteoporosis. We compared the anti-fracture efficacy and the rapidity of action of various agents versus placebo and versus risedronate.
Introduction: Adjuvant endocrine therapy induces bone loss and increases fracture risk in women with hormone-receptor positive, early-stage breast cancer (EBC). We aimed to update a previous position statement on the management of aromatase inhibitors (AIs) induced bone loss and now included premenopausal women.
Methods: We conducted a systematic literature search of the medical databases from January 2017 to May 2020 and assessed 144 new studies.
Context: Denosumab discontinuation is characterized by an increase in bone turnover overriding pre-treatment status, a rapid bone loss in the majority and multiple vertebral fractures (VFx) in some patients.
Methods: A working group of the European Calcified Tissue Society (ECTS) performed an updated systematic review of existing literature on changes of bone turnover, bone mineral density (BMD), and fracture risk after denosumab discontinuation and provided advice on management based on expert opinion.
Results: Important risk factors for multiple VFx following denosumab cessation are prevalent VFx, longer duration off therapy, greater gain in hip BMD during therapy, and greater loss of hip BMD after therapy according to a retrospective analysis of the FREEDOM Extension Study.
Context: Consensus regarding diagnosis and management of osteoporosis in premenopausal women (PW) is still lacking due to few studies carried out in this population.
Design: The European Calcified Tissue Society and the International Osteoporosis Foundation convened a working group to produce an updated review of literature published after 2017 on this topic.
Results: Fragility fractures in PW are rare and mostly due to secondary osteoporosis (ie, in presence of an underlying disease such as hormonal, inflammatory, or digestive disorders).
Article Synopsis
- The study looked at how many fractures were not reported by postmenopausal women over about 9 years, finding 992 total fractures but 21.3% of them weren't reported.
- It included 3,560 women aged 60-85, and researchers called them each year to check for fractures they might have missed.
- They found that fractures in certain places, like the spine, were missed more often than in others, showing that people might not know they had a fracture or forget to tell someone.
The current health crisis caused by COVID-19 is a challenge for oncology treatment, especially when it comes to radiotherapy. Cancer patients are already known to be very fragile and COVID-19 brings about the risk of severe respiratory complications. In order to treat patients safely while protecting medical teams, the entire health care system must optimize the way it approaches prevention and treatment at a time when social distancing is key to stemming this pandemic.
View Article and Find Full Text PDFArticle Synopsis
- The VERO study found that teriparatide reduced the risk of vertebral and clinical fractures in women with osteoporosis compared to risedronate.
- A post-hoc analysis examined the impact of psychotropic medications and proton pump inhibitors (PPIs) on fracture risks among participants.
- Results showed that users of PPIs had a significantly higher risk of new vertebral fractures, while benzodiazepine/hypnotic users had an increased risk of clinical fractures, but the treatment benefits of teriparatide remained consistent regardless of medication use.